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Abstract - The peroxisome proliferator-activated receptor gamma (PPARγ) is a gene candidate for the onset of type 2 
diabetes mellitus (T2DM). We investigated the association of the PPARγ Pro12Ala gene with the onset of T2DM for the 
first time in the Serbian population. The study population consisted of 197 controls and 163 T2DM patients. The 12Ala 
allele tended to be more frequent in the group of T2DM patients (0.11) compared to the control subjects (0.09). The 
results from this study indicate that the PPARγ2 12Ala allele presents a non-significant risk factor for T2DM deve-
lopment in the Serbian population. 
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INTRODUCTION 
Peroxisome proliferator-activated receptor gamma 
(PPARγ) is a member of the PPAR subfamily of 
nuclear receptors and appears to be an important 
regulator of adipogenesis (Kubota et al., 1999). This 
transcription factor is activated by prostaglandin 
derivatives and antidiabetic synthetic thiazolidindio-
nes, resulting in a powerful adipogenic response and 
enhanced insulin (INS) sensitivity (Brun et al., 1996). 
PPARγ is encoded by a single gene that gives rise 
through alternative splicing to four isoforms (γ1, γ2, γ3 
and γ4), which are transcribed from four different 
promoters and differ in their first exons. All of the 
transcripts yield the same protein, except for the γ2 
transcript, which codes for 30 additional amino acids 
on the N terminus (Ackert-Bicknell and Rosen, 2006). 
The PPARγ2 isoform is almost exclusively expressed 
in adipose tissue, while PPARγ1 is widely expressed 
(Fajas et al., 1997). 
Homozygous PPARγ-deficient mice had lethal 
embryos due to placental dysfunction (Kubota et 
al., 1999). Unexpectedly, the heterozygous PPARγ-
deficient mice were partially protected from high-
fat (HF) diet-induced obesity and INS resistance. 
Thus, it appears that the amount of PPARγ plays a 
critical role in adypocyte hypertrophy and the 
development of INS resistance under a HF diet 
(Kubota et al., 1999). A Pro12Ala substitution has 
been detected in the PPARγ2 gene (Yen et al., 1997) 
and this amino acid is located in the PPARγ2 do-
main that enhances ligand-independent activation 
(Werman et al., 1997). This amino acid is highly 
conserved. Codon 12 in the mouse PPARγ2 gene is 
proline (Yen et al., 1997). The Pro12Ala substi-
tution is associated with decreased receptor activity, 
lower body mass index (BMI) and improved INS 
sensitivity (Deeb et al., 1998). It is likely that two 
alleles of PPARγ interact with environmental fac-
tors such as a HF diet leading to an increase in the 
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incidence of type 2 diabetes mellitus (T2DM) 
(Heikkinen et al., 2009). 
Many studies were undertaken in order to point 
out the association of PPARγ2 Pro12Ala polymor-
phism with a susceptibility to T2DM. The majority of 
them showed the association of this gene 
polymorphism with T2DM development and also 
observed that the Pro12 allele is the risk allele for its 
onset (Mori et al., 2001; Douglas et al., 2001; Memi-
soglu et al., 2003; Ghoussaini et al., 2005). Studies 
from Germany (Ringel et al., 1999) and Italy (Mancini 
et al., 1999) have shown no association between 
Pro12Ala polymorphism and T2DM onset. The 
opposite was observed in four other studies (Sram-
kova et al., 2002; Malecki et al., 2003; Lindi et al., 2002; 
Evans et al., 2001) where results suggested a trend of 
increased 12Ala allele frequency in the T2DM patients 
compared to the control subjects, but with no 
statistical significance. Taking into consideration these 
controversial results about the association of PPARγ2 
Pro12Ala polymorphism with T2DM onset across the 
populations and the absence of data for our 
population, in this study we have analyzed, for the 
first time, the PPARγ2 Pro12Ala polymorphism in 
both non-diabetic and diabetic patients in Serbia. 
Thus, the aim of this study was to investigate which of 
these two alleles, if either, represents a possible risk 
factor for development of T2DM. 
MATERIALS AND METHODS 
Study population 
A local Ethical Review Committee approved the 
case-control study and each participant gave writ-
ten informed consent to participate in it. The study 
population consisted of 360 Caucasian subjects 
from Belgrade, Serbia. The control group (n=197) 
consisted of healthy volunteers who were under-
going an annual medical check-up at the Occu-
pational Medicine Center, INN Vinča. The T2DM 
patients (n=163) were recruited from the Endo-
crinology Clinic of the Military Medical Academy 
(MMA), Belgrade, and from the Institute of En-
docrinology, Diabetes and Metabolism Diseases of 
the Clinical Center of Serbia (CCS), Belgrade. 
T2DM was diagnosed according to World Health 
Organization criteria (WHO, 1985).  
Anthropometric and biochemical measurements 
Anthropometric measurements included BMI (kg/m2) 
and waist-to-hip ratio (WHR). The waist 
circumference was measured at the midpoint between 
the iliac crest and the lower rib margin, and the hip 
circumference was measured around the maximum 
circumference of the buttocks (posteriorly) and the 
symphysis pubis (anteriorly). Systolic and diastolic 
blood pressures were measured twice in the right arms 
of the subjects who had been resting for at least 10 min 
in a comfortable position. Fasting blood samples for the 
analyses of plasma glucose (GLU) and insulin (INS) 
concentration were obtained in the morning after 12-h 
fasting, and 120 min after breakfast. Plasma GLU 
concentration was analyzed using the GLU oxidase 
method by Beckman Glucose Analyzer II (Beckman 
Instruments, Fullerton, CA) and the hexokinase 
method by Olympus AU2700 (Olympus Diagnostics 
GmbH, Hamburg, Germany). Plasma INS 
concentration was determined by RIA kit (INEP, 
Zemun, Belgrade, Serbia). INS resistance was estimated 
according to the homeostasis model assessment 
(HOMA-IR) method from fasting GLU and INS 
concentrations using the formula: INS (μU/ml) x GLU 
(mmol/L)/22.5 (Matthews et al., 1985). Glycosylated 
hemoglobin (HbA1c) was measured following an 
overnight fast using Olympus AU2700 (Olympus 
Diagnostics GmbH, Hamburg, Germany). 
Lipids Measurement 
Lipid concentrations were determined in serum 
collected after overnight fasting. The total plasma 
cholesterol (TC) and triglyceride (TG) levels were 
determined on Monarch Plus apparatus (Instru-
mentation Laboratory, Lexington, KY) using enzy-
matic colorimetric methods. High-density lipopro-
tein cholesterol (HDLC) was determined after dex-
tran sulfate-Mg21 precipitation of VLDL and low-
density lipoprotein cholesterol (LDLC), using the 
CHOD-PAP method. LDL cholesterol was calcula-
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ted according to the Friedewald formula for parti-
cipants with TG levels < 4.5mmol/L (WHO, 1985).  
Genetic analysis 
Genomic DNA was isolated from whole blood 
samples collected with EDTA and purified by the 
proteinase K/phenol extraction method (Kunkel et 
al., 1977). The Pro12Ala polymorphism was detected 
by the PCR (polymerase chain reaction) method. 
The sequences of the primers were 5'- 
TCTGGGAGATTCTCCTATTGGC – 3' (forward 
primer) and 5' – CTGGAAGACAAACTACAAGAG 
– 3' (reverse primer) (Hara et al., 2000). The forward 
primer contained one nucleotide mismatch 
(underlined), which made it possible to use the 
restriction enzyme Hin6I for the detection of 
Pro12Ala polymorphism. The conditions for PCR 
were in a 25 μl reaction mixture containing 200 ng of 
genomic DNA, 0.15μM of the primers, 2 mM MgCl2, 
200 μM dNTP each and 1U of Taq polymerase. The 
reaction mixtures were incubated at 94ºC for 5 min, 
followed by 35 cycles of denaturation at 94ºC for 30 
s, annealing at 52ºC for 30 s and extension at 72ºC 
for 30 s. The PCR products were digested with Hin6I 
at 37ºC overnight. The Pro12 allele gave one 154 bp 
fragment whereas the 12Ala allele gave 133 bp and 
21 bp fragments. The digestion products were loaded 
onto a 10% polyacrylamide gel for genotyping and 
run for 2 h in an electric field at 12 V/cm. The gels 
were stained with silver nitrate and visualized using a 
GDS8000 gel documentation system (Ultra Violet 
Products, Inc., Upland).  
Statistical analysis 
All statistical analyses were carried out using 
Statistica Version 5 (1997) software package 
(StatSoft, Inc.). Differences with two-tailed alpha-
probability (P) ≤ 0.05 were considered significant. 
The allelic frequencies and genotype distribution 
were estimated using the gene counting method. 
Differences in both allele and genotype frequency 
distribution between the studied groups were esti-
mated by the chi-square (χ2) test. Deviation from 
Hardy-Weinberg equilibrium was also assessed 
using the χ2 test. For cross comparison (2x2) of 
parameters, which have one of two possible out-
comes (the presence of T2DM according to sex, 
smoking and hypertension), the Fisher exact two-
tailed test was used. Differences in continuous 
variables between the groups were tested with 
Student's t-test and one way ANOVA with adequate 
post hoc tests when the distribution of the variable 
or the logarithmically transformed variable 
approached a normal distribution. Otherwise, the 
Mann-Whitney U test and Kruskal-Wallis ANOVA 
tests were used. To estimate an association of the 
PPARγ2 Pro12Ala polymorphism genotypes with 
the onset of T2DM, both univariate and mul-
tivariate logistic regression analyses were performed 
and the results were presented as both unadjusted 
and adjusted odds ratios (OR) and their confidence 
intervals (95% CI). The crude effect of the Pro12Ala 
polymorphism was adjusted for the variables that 
were statistically significant for the onset of T2DM 
in the univariate logistic regression analysis. 
RESULTS 
Description of the population 
The clinical parameters for both control and of 
T2DM patient groups are shown in Table 1. 
Differences between the groups were significant for 
gender, age, BMI, systolic blood pressure, diastolic 
blood pressure, total cholesterol, HDL cholesterol, 
LDL cholesterol, triglycerides and hypertensive 
status. In general, the patients with T2DM were 
significantly older and had significantly higher BMI 
values, SBP and DBP levels, TC, LDLC and TG 
plasma levels and lower HDL levels compared to 
the control subjects.  
Effect of PPARγ Pro12Ala gene polymorphism on 
susceptibility to T2DM 
The genotype frequency distribution for PPARγ2 
Pro12Ala gene  polymorphism was in Hardy-Wein- 
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berg equilibrium for both control and T2DM 
patients. The 12Ala allele frequency was slightly 
higher in the T2DM patients (0.11) compared to 
the control (0.09), without any statistical significan-
ce (Table 2). The distribution of the genotype fre-
quencies was not significantly different between the 
studied groups (Table 2).  
The 12Ala allele T2DM female carriers had 
significantly (p<0.05) lower fasting INS concen-
tration than T2DM women with Pro12Pro geno-
type (Table 3.). 
The carriers of 12Ala allele had non-significant 
unadjusted OR (1.10) for the onset of T2DM. After 
an adjustment of the factors that have been 
significantly associated with T2DM in univariate 
analysis (age, BMI, TC, LDLC, HDLC, TG and 
hypertensive status), Ala12 allele carriers show 
increased OR (1.81), CI (0.83-3.95) for DMT2 
onset, however it was not statistically significant 
(Table 4 and Fig. 1). 
DISCUSSION 
This study examined PPARγ2 Pro12Ala gene 
polymorphism as a risk factor for the onset of 
T2DM in the Serbian population. No association 
between Pro12Ala polymorphism and T2DM was 
found in the population sample. A non-significant 
increase in the risk for T2DM onset was found for 
Ala12 allele carriers. A significantly lower fasting 
INS concentration associated with 12Ala allele 
carriers was observed only in the group of T2DM 
women. 
Table 1. The clinical and histopathological characteristics of patients
p 
Characteristics Control subjects Type 2 diabetic subjects t-test 
M/F n (%)    
95(48.22)/ 
102(51.78) 
127(77.91)/ 
36(22.09) <0.01* 
Age (years) 34.9±12.2 55.1±9.3 <0.01 
BMI (kg/m2) 24.3±3.7 28.3±4.5 <0.01 
SBP (mmHg) 117.7±10.2 139.9±18.9 <0.01# 
DBP (mmHg) 76.2±6.4 86.2±11.9 <0.01# 
TC (mmol/L) 5.6±1.2 6.3±1.3 <0.01 
HDLC (mmol/L) 1.40±0.36 1.05±0.28 <0.01 
LDLC (mmol/L) 3.56±1.04 4.11±.25 <0.01 
TG (mmol/L) 1.29±0.76 2.84±2.71 <0.01 
Hypertensive - n (%) 2 (1.02) 66 (44.30) <0.01* 
Smokers - n (%) 100 (50.76) 65 (49.24) NS* 
 
BMI – body mass index; SBP – systolic blood pressure; DBP – diastolic blood pressure; TC – total cholesterol; HDLC high-density 
lipoprotein cholesterol; LDLC – low-density lipoprotein cholesterol; TG – triglycerides. Values are mean ± SD for age, BMI, SBP, DBP, TC, 
HDLC, LDLC and TG; * -– Fisher exact two-tailed test (χ2 - test); # –-Mann-Whitney U test ; NS – non-significant. 
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Table 3. Anthropometric and biochemical measurements of T2DM patients stratified by gender according to the Pro12Ala 
polymorphism of the PPARγ2 gene. 
Characteristic          T2DM women (n=36)                                                 T2DM men (n=127) 
                                    Pro/Pro            Ala-carriers               p                   Pro/Pro            Ala-carriers                p                           
Age (years)   59.3±9.4 56.67±7.02 NS 53.4±8.5 56.7±8.0 NS 
BMI (kg/m2) 26.8±4.0 29.9±8.3 NS 28.4±4.1 28.2±5.4 NS 
TC (mmol/L) 6.5±1.9 6.0±0.93 NS 6.2±1.3 6.2±1.3 NS 
HDLC (mmol/L) 1.24±0.32 1.25±0.03 NS 1.01±0.26 1.05±0.25 NS 
LDLC (mmol/L) 4.19±1.65 3.99±0.72 NS 4.07±1.29 4.11±0.95 NS 
TG (mmol/L)          2.30±1.43 1.72±0.61 NS 2.61±2.13 2.42±1.40 NS 
Fasting 
glucose(mmol/L) 7.8±2.0 10.6±2.9 NS 8.4±2.8 8.5±2.2 NS 
2h glucose(mmol/L) 11.3±4.7 15.1±1.3 NS 11.4±4.0 10.7±3.3 NS 
Fasting 
insulin(mU/L) 20.2±10.8 9.5±4.5 <0.05 24.5±14.3 31.1±15.9 NS 
2h insulin(mU/L) 86.4±88.0 23.8±12.4 NS 68.8±51.9 72.7±50.1 NS 
WHR   0.87±0.07 0.86±0.05 NS 1.03±0.07 1.04±0.05 NS 
HOMA-IR 7.40±6.16 4.24±1.99 NS 8.89±4.92 11.78±7.65 NS 
HbA1C (%) 6.70±1.20 8.47±0.51 NS 7.48±1.53 7.12±1.26 NS 
SBP (mmHg) 138.5±14.5 136.2±14.1 NS 137.7±17.1 136.6±14.7 NS 
DBP (mmHg) 81.0±7.4 77.7±2.5 NS 86.1±10.6 88.9±4.5 NS 
 
BMI – body mass index; TC – total cholesterol; HDLC – high-density lipoprotein cholesterol; LDLC – low-density lipoprotein cholesterol; 
TG – triglycerides; WHR – waist-to-hip ratio; HOMA-IR – Homeostasis Model assessment – insulin resistance; HbA1C – glycosylated 
haemoglobin; SBP – systolic blood pressure; DBP – diastolic blood pressure. Values are mean ± SD for all measured parameters. NS – non-
significant. 
Table 2. Genotype distribution and allele frequencies for PPARγ2 Pro12Ala gene polymorphism in the groups of control and T2DM 
patients 
 Control subjects Type 2 diabetic patients p 
Genotype n % n % χ2 
ProPro 160 81.22 130 79.75  
ProAla + AlaAla 37 18.78 33 20.25 NSª 
Pro allele/Ala allele 0.91/0.09 0.89/0.11 NS 
 
ª - Fisher exact two-tailed test 
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Figure 1. 
 
Results involving the role of PPARγ2 Pro12Ala 
gene polymorphism in T2DM onset vary across 
populations as well as the frequency of 12Ala allele 
in the T2DM patients compared to controls, suggest 
genetic heterogeneity (Ludovico et al., 2007). Our 
finding of 12Ala allele frequency in the controls is 
in agreement with the previous study that found a 
north-south frequency decrease gradient in Europe 
(Ludovico et al., 2007). Considering the risk of 
T2DM onset and 12Ala allele frequency, our fin-
ding is in accordance with previous results (Ringel 
et al., 1999; Mancini et al., 1999; Ludovico et al., 
2007). A reduced risk of T2DM in the Ala12 
carriers is greater in Asia than in Europe. Among 
Europeans, it is higher in northern Europe, barely 
significant in central Europe, and nonexistent in 
southern Europe (Ludovico et al., 2007). The same 
nonexistence of reduced risk for T2DM in Ala12 
carriers is present in our population, as one of the 
southern European populations. The trend for 
increased risk for T2DM in PPARγ2 12Ala allele 
carriers compared with non-carriers was observed 
in our population. This is similar to results from 
other (Czech, Polish, Finnish and German) diabetes 
studies (Sramkova et al., 2002, Malecki et al., 2003; 
Lindi et al., 2002; Evans et al., 2001).  
However, the present data show that T2DM 
female carriers of 12Ala allele had significantly lo-
wer fasting INS than those with a Pro12Pro geno-
type. This is in agreement with the results of 
impaired INS secretion in 12Ala T2DM individuals 
in two other populations (Mori et al., 2001; Sram-
kova et al., 2002). In addition, the Pro12Ala poly-
morphism in the PPARγ2 gene might be involved in 
a differential regulation of INS secretion in 
response to increased free fatty acids (FFAs) in 
healthy humans (Stefan et al., 2001). The 12Ala 
allele carriers have a reduced capacity for INS 
secretion (Stefan et al., 2001).   
The PPAR-gamma is expressed in human beta-
cells (Dubois et al., 2000). Therefore, Pro12Ala gene 
polymorhism could interfere with pancreatic function 
and have an impact on INS secretion and sensitivity 
and GLU homeostasis. 12Ala allele might be a risk 
factor for INS deficiency, and therefore contribute to 
the progression of T2DM. Heikkinen et al., (2009) 
reported differences in gene expression changes 
associated to the Pro12Ala variant between the two 
diets. This supports the hypothesis that the Pro12Ala 
phenotype depends on nutritional status and suggests 
PPARγ2 as an environmental sensor (Heikkinen et al., 
2009). Hence, PPARγ2 may provide a better, probably 
Pro12Ala genotype-dependent treatment strategy for 
INS resistance in T2DM. 
In conclusion, the non-existence of reduced risk 
of T2DM in the Ala12 carriers in the Serbian 
population is similar to that of populations with the 
same geographic origin. The results of our case-
control study indicate a trend towards 12Ala allele as a 
Table 4. PPARγ2 Pro12Ala gene polymorphism relative odds ratios (ORs) for onset T2DM unadjusted and adjusted for differences in 
significant clinical risk factors # 
Genotype classes                                        Unadjusted OR (95% CI)                   p                       Adjusted OR(95% CI)                       p  
ProPro vs. ProAla + AlaAla                               1.10 (0.65-1.86)                       0.73                           1.81 (0.83-3.95)                           0.14 
# see results 
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risk factor for T2DM development. Considering the 
number of the participants in this study, as well as the 
existence of the European north-south gradient, there 
is a need to confirm the present findings in larger 
replication studies in different populations, 
particularly those from surrounding south-eastern 
European countries. Further results are needed for 
establishing PPARγ2 Pro12Ala gene polymorphism as 
a risk factor for the onset of complex, chronic and 
polygenic disease such as T2DM.  
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Рецептор активиран пролифератором перок-
сизома гама (PPARγ) је ген кандидат за настанак 
дијабетеса типа 2 (DMT2). Испитивали смо по 
први пут у српској популацији асоцијацију 
полиморфизма Pro12Ala у гену за PPARγ са 
настанком DMT2. Студију је чинила популација 
од 197 контрола и 163 пацијента са DMT2. Алел 
12Ala је био чешћи у групи пацијената са DMT2 
(0.11) у односу на контролну групу (0.09). 
Резултати ове студије указују да алел 12Ala 
PPARγ2 не представља значајан фактор ризика за 
настанак DMT2 у српској популацији.  
 
